Company intelligence / Profile preview

Gritscience

Beijing, Beijing, Chinanjtuoao.com ↗

Ownership: Private
Development stage: Preclinical

Overview

GT101 (non-gene-engineered TIL program) is in Phase 2 (pivotal) trials and on track to file for Biologics License Application (BLA) in 2025. GT201 (genetically engineered TIL product) received IND approval in China in July 2023 and IND clearance from the U.S. FDA in August 2024.

Therapeutic areas: OncologyRare DiseasesInfectious Diseases
Modalities: Cell therapyGene therapyAAV
Industry: Biotech

Beyond the preview

Go deeper on Gritscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gritscience.

Explore the full profile